Back to today’s briefing

Story perspectives

FDA Biologics Chief Resigns Amid Political Turmoil

8/2/2025

29 2

Summary

Story summary

Vinay Prasad's 84-day leadership of the FDA's biologics division was cut short by intense political backlash over his controversial decisions on gene therapies and COVID-19 vaccines. His exit underscores the turbulent intersection of science and politics at the FDA, especially concerning rare diseases. In a parallel move, Trump urges pharmaceutical companies to match U.S. drug prices with those in other affluent countries.

History

Historical Context

In 2004, the FDA approved the first gene therapy, a landmark decision that catalyzed extensive research, resulting in over 1,000 clinical trials by 2021. This approval, alongside the National Institutes of Health, highlights ongoing tensions between scientific progress and regulatory challenges, echoing historical FDA controversies. These dynamics are crucial for shaping future health policies and public trust in medical advancements.

1 of 2

Story summary

Vinay Prasad's 84-day leadership of the FDA's biologics division was cut short by intense political backlash over his controversial decisions on gene therapies and COVID-19 vaccines. His exit underscores the turbulent intersection of science and politics at the FDA, especially concerning rare diseases. In a parallel move, Trump urges pharmaceutical companies to match U.S. drug prices with those in other affluent countries.

1 / 2